Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 18/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 18/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 14/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 13/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 8/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 8/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 3/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 3/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7725966 | 0.91 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL7721547 | 0.90 | GABRG2 (0.95) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL7718010 | 0.90 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL17088099 | 0.90 | GABRG2 (0.82) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL639547 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL29518128 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL4990402 | 0.89 | GABRG2 (0.80) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL7721750 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL29712107 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL29712005 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490344-B1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC SIDE EFFECTS | WISYS TECHNOLOGY FOUND INC (US) | 2008-03-19 | — | — | EP | claimed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | claimed |
| US-12054491-B2 | Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators | UWM RESEARCH FOUNDATION, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230103216-A1 | GABA(A) RECEPTOR MODULATORS AND METHODS TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | UWM RESEARCH FOUNDATION, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11447495-B2 | Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators | UWM RESEARCH FOUNDATION, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-109790170-B | GABA (A) receptor modulators and methods of controlling airway hyperresponsiveness and inflammation in asthma | UWM研究基金会有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20220079952-A1 | Uses of Radiation and Benzodiazepine Derivatives in Cancer Therapies | UNIV EMORY (US) | 2022-03-17 | — | — | US | disclosed |
| EP-3500573-B1 | GABA(A) RECEPTOR MODULATORS AND METHODS TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | UWM RES FOUNDATION INC (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20210284649-A1 | GABA(A) RECEPTOR MODULATORS AND METHODS TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-09-16 | — | — | US | disclosed |
| WO-2020242923-A1 | USES OF RADIATION AND BENZODIAZEPINE DERIVATIVES IN CANCER THERAPIES | EMORY UNIVERSITY (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20190300534-A1 | GABAERGIC LIGANDS AND THEIR USES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-10-03 | — | — | US | disclosed |
| US-7235656-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-7119196-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060003995-A1 | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20040082573-A1 | Anxiolytic agents with reduced sedative and ataxic effects | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-29 | — | — | US | disclosed |
| WO-2003082832-A2 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRG2 14/4885GABRB3 7/4885GABRA5 6/4885 |
| US-12054491-B2 | Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators | GABRA5, GABRA4, GABRA1 | GABRG2 14/4885GABRB3 8/4885GABRA5 1/4885 |
| US-20220079952-A1 | Uses of Radiation and Benzodiazepine Derivatives in Cancer Therapies | GABBR1, GABBR2, GABRA3 | GABRG2 13/4885GABRB3 9/4885GABRA5 8/4885 |
| US-20230103216-A1 | GABA(A) RECEPTOR MODULATORS AND METHODS TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | GABRA4, GABRA5, GABRB1 | GABRG2 15/4885GABRB3 5/4885GABRA5 2/4885 |
| US-11447495-B2 | Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators | GABRA4, GABRA5, GABRA1 | GABRG2 13/4885GABRB3 9/4885GABRA5 2/4885 |
| US-20060003995-A1 | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects | GABRE, GABRA6, GABRA5 | GABRG2 21/4885GABRB3 14/4885GABRA5 3/4885 |
| US-20040082573-A1 | Anxiolytic agents with reduced sedative and ataxic effects | GABRA3, GABRA2, GABRA1 | GABRG2 14/4885GABRB3 7/4885GABRA5 6/4885 |
| US-20210284649-A1 | GABA(A) RECEPTOR MODULATORS AND METHODS TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA | GABRA4, GABRA5, GABRB1 | GABRG2 15/4885GABRB3 5/4885GABRA5 2/4885 |
| US-20190300534-A1 | GABAERGIC LIGANDS AND THEIR USES | GABRA3, GABRB3, GABRA2 | GABRG2 11/4885GABRB3 2/4885GABRA5 14/4885 |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | GABRG2 14/4885GABRB3 8/4885GABRA5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.